U.S. SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.

FORM 12b-25

NOTIFICATION OF LATE FILING

SEC FILE NUMBER: 0-33219

						_
				CUS	SIP NUMBER:	
Check One):	o Form 10-K	o Form 20-F	o Form 11-K	⊠ Form 10-Q	o Form N-SAR	
	For Period Ended:		June 30, 2002		_	
	o Transition Report on o Transition Report on o Transition Report on o Transition Report on o Transition Report on For the Transition Perio	Form 20-F Form 11-K Form 10-Q Form N-SAR				
	F	Read Instruction (on back pag	e) Before Preparing Form. F	Please Print or Type.		_
	Nothing in this form s	hall be construed to imply t	hat the Commission has ve	rified any information cor	ntained herein.	
f the notificatio	n relates to a portion of the	filing checked above, identif	fy the Item(s) to which the no	otification relates:		
PART I — REC	GISTRANT INFORMAT	ION				
Biokeys Pharma	nceuticals, Inc.					_
Full Name of Re	egistrant					_
Former Name if	Applicable					_
9948 Hibert Stre	eet, Suite 100					_
Address of Princ	cipal Executive Office (Str	eet and Number)				_
San Diego, CA S	92131					_
City, State and Z	Zip Code					

PART II — RULES 12B-25(B) AND (C)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate).

- 🗵 (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail the reasons why Form 10-K and Form 10-KSB, 20-F, 11-K, 10-Q and Form 10-QSB, N-SAR, or the transition report or portion thereof could not be filed within the prescribed period.

The Registrant's Chief Financial Officer has been overseas on a business trip and will not be available to review financial statements with Registrant's Chief Executive Officer and to sign the required certification under the Sarbanes-Oxley Act of 2002 until late on August 14 or August 15, 2002.

PART IV — OTHER INFORMATION

identify report(s). \boxtimes Yes

(1) Name and telephone number of person to contact in regard to this notification.

o No

Seymour H. Bucholz, Esq.

(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities and Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no,

212

661-2150

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? 🗵 Yes o No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

It is anticipated that there will be a significant change in quarterly and six-month results from the corresponding periods in 2001, reflected in the earnings statement to be included in the subject report. It is estimated that the operating loss for the six-months ended June 30, 2002 will be approximately \$(1,630,000) compared with an operating loss of \$(5,338,348) for the same period in 2002, due primarily to the elimination, after December 31, 2001, of goodwill amortization expense of \$1,902,367 per quarter included in the prior year's results, plus a reduction in research and development expense partially offset by an increase in interest expense.

BIOKEYS PHARMACEUTICALS, INC.

(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 14, 2002 By: s/ WARREN C. LAU

Name: Warren C. Lau Title: President

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

General Instructions

- 1. This form is required by Rule 12b-25 (17 CFR 240. 12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.
- One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the form will be made a matter of public record in the Commission files.
- 3. A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class of securities of registrant is registered.

- 4. Amendments to the notifications must also be filed on form 12b-25 but need not restate information that has been correctly furnished. The form shall be clearly identified as an amended notification.
- 5. *Electronic filers*. This form shall not be used by electronic filers unable to timely file a report solely due to electronic difficulties. Filers unable to submit a report within the time period prescribed due to difficulties in electronic filing should comply with either Rule 201 or Rule 202 of Regulation S-T (§232.201 or §232.202 of this chapter) or apply for an adjustment in filing date pursuant to Rule 13(b) of Regulation S-T (§232.13(b) of this Chapter).